Carboplatin + Pemetrexed + Vorinostat

The combination of carboplatin + pemetrexed + vorinostat is a chemotherapy regimen that has been studied primarily for the treatment of non-small cell lung cancer (NSCLC). This combination brings together two established chemotherapy agents (carboplatin and pemetrexed) with vorinostat, a histone deacetylase (HDAC) inhibitor.\n\n## Composition and Mechanism\n\nThis combination therapy works through multiple mechanisms:\n\n- **Carboplatin**: A platinum-based chemotherapy that forms crosslinks with DNA, interfering with DNA repair mechanisms and causing cell death[2].\n- **Pemetrexed**: An antifolate agent that inhibits multiple enzymes involved in folate metabolism and DNA synthesis[2][3].\n- **Vorinostat**: A histone deacetylase inhibitor that exerts anticancer effects through both histone and non-histone mediated mechanisms[1][6].\n\nThe addition of vorinostat to carboplatin and paclitaxel has shown enhanced efficacy in clinical trials for NSCLC, with a confirmed response rate of 34% compared to 12.5% with placebo[1][6].\n\n## Clinical Evidence\n\nWhile the search results don't specifically mention trials of the exact carboplatin + pemetrexed + vorinostat combination, they do provide information about:\n\n1. Carboplatin + pemetrexed as an established combination for non-small cell lung cancer and mesothelioma[2][3][7][8].\n2. Carboplatin + paclitaxel + vorinostat, which showed improved response rates and trends toward better progression-free and overall survival compared to carboplatin + paclitaxel alone in NSCLC patients[1][6].\n\nThe carboplatin + pemetrexed combination is commonly used for the treatment of advanced non-squamous NSCLC and has shown efficacy in both younger and elderly patients[3].\n\n## Administration\n\nBased on the information about similar combinations:\n\n- Carboplatin is typically administered intravenously on day 1 of a 21-day cycle.\n- Pemetrexed is also administered intravenously on day 1.\n- Vorinostat, when used with carboplatin and paclitaxel, was given orally at 400 mg daily on days 1-14 of each 3-week cycle[1][6].\n\nPatients receiving pemetrexed typically also receive folic acid supplements and vitamin B12 injections to reduce side effects[2][7].\n\n## Side Effects\n\nCommon side effects of this combination may include:\n\n- Hematologic toxicities (anemia, thrombocytopenia, neutropenia)\n- Fatigue\n- Nausea and vomiting\n- Anorexia\n- Sensory neuropathy\n- Myalgia\n- Stomatitis\n- Diarrhea\n\nThe addition of vorinostat to platinum-based chemotherapy has been associated with increased grade 4 platelet toxicity, as well as more frequent nausea, emesis, fatigue, dehydration, and hyponatremia[1][6].\n\nThis combination represents an approach to enhance the efficacy of standard chemotherapy through the addition of an epigenetic modulator (vorinostat), which has shown promise in clinical studies for advanced NSCLC.